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Background: Non-alcoholic Fatty Liver Disease (NAFLD) embodies the hepatic 
manifestation of metabolic syndrome, commonly associated with obesity,
hyperinsulinaemia, peripheral insulin resistance, diabetes, hypertension,
hypercholesterolaemia and hypertriglyceridaemia (Sanyal, 2002). NAFLD is recently 
conceded to be a global epidemic burden, being ranked as the second leading cause of 
preventative death (Younossi, 2008). Since the pathogenesis of NAFLD remains 
controversial, no established pharmacological agent has been developed that effectively 
targets or prevents excessive fat accumulation in the hepatocytes and, as a result, 
current treatments are primarily symptomatic. Chinese herbal medicine has become a 
growing focus for Western medical research in the quest for more effective treatments 
since various Chinese herbal formulae are used in Asian countries for hepatic and 
metabolic syndromes (Chen et al, 2006, Hollander and Merchanick 2008).
Objective: To determine whether obesity related NAFLD could be induced in healthy 
rats by dietary manipulation alone and to investigate the effects of three Chinese herbal 
formulae in these animals on relevant variables on in vivo measures and on tissue 
analyses post mortem.
Design: The research comprised of two related studies. Study one was a between 
subjects equivalent group experiment with repeated measures, with the rats randomly 
divided among six intervention groups. Five groups were continuously fed a high fat 
diet (HFD) and one group fed a standard laboratory chow for 11 weeks until sacrifice. 
Study two entailed the collection of liver and adipose tissues immediately post mortem. 
These tissue weights were recorded and the livers were used to measure hepatic 
triglyceride content and for histological examination of the rat liver.
Participants and interventions: 56 male Sprague Dawley rats, six weeks old and 
weighing between 170 - 210g were randomly divided among six intervention groups. 
Five groups were continuously fed a HFD and one group, a standard laboratory chow 
for 11 weeks until sacrifice. After a five week induction period, the six week
l
intervention phase commenced with the allocated intervention administered daily by 
oral gavage. Blood collection occurred in the last week before sacrifice for subsequent 
analyses. The pharmacological interventions comprised Rosiglitazone (RSG); anti­
diabetic medication, SK0504 (S4), SK0506 (S6) and a decoction of SK0506 (DS6) as 
well as water for the two control groups. Note: S4 combines Jiao Gu Lan (Gynostemma 
pentaphyllum), San Qi (Panax notoginseng), Huang Lian (Rhizoma Coptidis) and Dan 
Shen {Salvia miltiorrhiza) and S6 combines Dan Shen {Salvia miltiorrhiza) and Zhi Zi 
{Fructus Gardenia Jasminodis).
Main outcome measures: Bodyweight, food and energy food intake; biochemical and 
hepatic analyses (plasma glucose, Non-esterified Fatty Acids (NEFA), cholesterol, 
triglycerides (TG), High Density Lipoprotein-Cholesterol (HDL-C), Alanine 
Transaminase (ALT), Aspartate Transaminase (AST) and hepatic triglycerides); and 
histopathological staining (to observe hepatic morphology) were measured.
Results: The results for the five week induction phase suggest that despite the 
difference in diet (HFD or standard chow) the rats regulated their energy intake as there 
was no significant difference in the increase in mean weight for the two diets.
During the intervention phase there were further increases in body weight that plateaued 
after four weeks, quite independent of diet or intervention. However, there was no clear 
relationship between caloric intake and weight gain in that there were significant 
differences between the two S6 groups and the others and yet this did not equate to any 
difference in weight gain.
At the end of the intervention period there was no significant difference between most 
groups in blood glucose levels and typically animals were within the healthy range. 
Therefore high fat feeding alone, particularly in a short period of time of ten weeks did 
not cause hyperglycaemia.
Within the intervention groups there was evidence of marked hyperlipidaemia with the 
HFD as evidenced by significant increases in NEFA, TG and cholesterol. In general, 
this was attenuated by the interventions. Notably both forms of the S6 intervention had 
a cardioprotective effect illustrated by the elevation of levels of HDL-C.
There were potentially hepatotoxie effects indicated by elevation of liver enzymes 
associated with HFD feeding alone that were supported by histopathological changes in 
the liver.
Post mortem comparisons included weights of adipose tissues, hepatic tissue and 
hepatic morphology for evidence of NAFLD. With the epidydimal, subcutaneous and 
inguinal fat deposits, there was a significant degree of fat accumulation in the HFD 
group compared with the chow group. RSG showed no beneficial effect with regard to 
fat accumulation, which contrasts with the effects of the two herbal formulae S4 and S6. 
There was no evidence of hepatomegaly in any group.
High fat feeding resulted in excess hepatic triglyceride levels which was attenuated by 
RSG, S4 and S6, with S6 being the most effective. Note that no intervention completely 
prevented this high fat feeding accumulation.
The significant increase in hepatic TG accumulation and plasma biochemical analysis 
(NEFA, TG and cholesterol) with the high fat feeding in control groups was supported 
from the histological findings of macro- and microvesicular steatosis fed the HFD alone. 
These histological changes were absent in animals fed the other HFD based 
interventions (S6, S4 and RSG). There was no discemable fibrosis in any of the groups.
Conclusion: HFD feeding alone produced NAFLD as hypertriglyceraemia,
hypercholesterolaemia and histological evidence of steatosis was observed. The three 
herbal formulae all attenuated the HFD’s hyperlipidaemic effects in relation to plasma 
TG, NEFA, cholesterol, HDL-C and hepatic TG as no steatosis was formed. However 
lack of difference in weights between standard chow and HFD fed rats during the 
induction and intervention phases suggests the model failed to produce obesity which 
may be due to the short period of 11 weeks of the dietary manipulation.
S4 and S6 both attenuated the effects on liver enzymes of the high fat diet, possibly 
indicating possible hepatoprotective effects with the values falling towards those for the 
Chow group. RSG by contrast elevated AST levels above those for HFD.
The two forms of S6; powder and decoction, compared in study one showed generally 
similar results.
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